Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Short Interest Update

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the target of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 200 shares, a decline of 86.7% from the October 15th total of 1,500 shares. Based on an average daily volume of 2,300 shares, the short-interest ratio is presently 0.1 days.

Clinuvel Pharmaceuticals Stock Up 0.1 %

Shares of CLVLY stock traded up $0.01 during mid-day trading on Wednesday, hitting $8.95. The stock had a trading volume of 1,450 shares, compared to its average volume of 2,716. The company’s 50-day simple moving average is $9.57 and its 200-day simple moving average is $9.76. Clinuvel Pharmaceuticals has a fifty-two week low of $8.42 and a fifty-two week high of $12.06.

Clinuvel Pharmaceuticals Increases Dividend

The firm also recently declared a dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a $0.0299 dividend. This is a boost from Clinuvel Pharmaceuticals’s previous dividend of $0.03. The ex-dividend date of this dividend was Monday, September 9th.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).